Full-Time

Scientist – NGS Core Lead

Posted on 11/7/2024

Alltrna

Alltrna

51-200 employees

Develops tRNA therapeutics for disease treatment

Biotechnology
Healthcare

Entry

Cambridge, MA, USA

Category
Computational Biology
Genomics
Biology Lab & Research
Biology & Biotech
Requirements
  • PhD in biology or a related discipline with 0-2 years of experience working in biotech or a related industry, or M.S. with 6+ years of relevant experience.
  • Expertise with a variety of Illumina-based NGS methods, including experience with RNA-centric methods and experience developing or implementing custom NGS methods.
  • Demonstrated ability to drive improvements in quality, reproducibility, and/or scale of NGS methods.
  • Experience interpreting NGS data in support of quality assessment, methodology improvement, and experimental troubleshooting.
  • Experience managing or coordinating work of a small team.
  • Demonstrated ability to implement and support technical and operational processes that contribute to the successful execution of scientific research at scale.
  • Excellent communication skills and the ability to clearly explain NGS methods and considerations around their application to team members of diverse backgrounds.
  • Detail-oriented and organized with a strong ability to manage multiple experiments in parallel.
Responsibilities
  • Support company-wide use of tRNA sequencing by coordinating and overseeing work of the NGS core.
  • Contribute to tRNA sequencing work by performing RNA extraction, library preparation, and data review.
  • Drive the continued improvement of tRNA sequencing by identifying and implementing solutions to problems of scale, reproducibility and quality of the method.
  • Coordinate with stakeholders relating to sequencing requests, supporting experimental design, sample submission, tracking experiment status, and troubleshooting unexpected results as needed.
  • Support the transition of sequencing methods from the late stages of their development to establish them as pipeline methods.

Alltrna focuses on developing tRNA therapeutics to treat diseases caused by genetic mutations. Their main product involves engineered tRNAs that can recognize and read stop codons, which are errors in the genetic code that lead to the production of incomplete proteins. By delivering the correct amino acids, these tRNAs help restore the production of full-length proteins, potentially addressing a wide range of diseases linked to nonsense mutations. Unlike other biotech companies, Alltrna is the first to explore the therapeutic potential of tRNA in this way, aiming to unlock new treatment options for patients with specific genetic disorders. The goal of Alltrna is to provide effective treatments that target the root causes of diseases, improving the quality of life for those affected.

Company Stage

Series B

Total Funding

$154.7M

Headquarters

Cambridge, Massachusetts

Founded

2018

Growth & Insights
Headcount

6 month growth

0%

1 year growth

-12%

2 year growth

23%
Simplify Jobs

Simplify's Take

What believers are saying

  • Raised $109M in Series B to advance tRNA medicines for Stop Codon Disease.
  • Growing market for genetic therapies supports Alltrna's tRNA therapeutic potential.
  • Advancements in LNP technology could enhance delivery of Alltrna's tRNA therapeutics.

What critics are saying

  • Potential competition from established RNA-based therapy companies like Moderna.
  • Complexity of tRNA biology may delay drug development and regulatory approval.
  • High development costs could strain financial resources without successful funding rounds.

What makes Alltrna unique

  • Alltrna is the first to decode tRNA biology for therapeutic use.
  • Their platform uses AI/ML to develop programmable molecules for disease treatment.
  • Alltrna targets nonsense mutations, restoring full-length protein production in genetic diseases.

Help us improve and share your feedback! Did you find this helpful?

INACTIVE